Eveline M. Dijkgraaf
Leiden, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.
Journal: Oncoimmunology
Published: February 28, 2018
A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 31, 2015
Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.
Journal: Cancer immunology, immunotherapy : CII
Published: March 30, 2015
Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01).
Journal: Breast cancer research and treatment
Published: October 10, 2014
Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer.
Journal: Oncoimmunology
Published: August 10, 2014
Effect of hypoxic stress on migration and characteristics of monocytes in uveal melanoma.
Journal: JAMA ophthalmology
Published: March 15, 2014
Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment.
Journal: Cancer research
Published: February 26, 2013
Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer.
Journal: Current pharmaceutical design
Published: February 10, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026